Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of calreticulin (CALR) as a therapeutic target in myeloproliferative neoplasms (MPNs), highlighting three recent studies that developed and evaluated antibodies against mutant CALR in pre-clinical models. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.